AbCellera Biologics Inc. ABCL Trading securities, cost
Trading securities, cost at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s trading securities, cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s trading securities, cost?
- AbCellera Biologics Inc. (ABCL) reported trading securities, cost of $32.5M in Q1 2026.
- How has AbCellera Biologics Inc.'s trading securities, cost changed year-over-year?
- AbCellera Biologics Inc.'s trading securities, cost increased by 0.6% year-over-year, from $32.3M to $32.5M.
- What is the long-term trend for AbCellera Biologics Inc.'s trading securities, cost?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s trading securities, cost has grown at a 20.7% compound annual growth rate (CAGR), from $18.5M to $32.5M.